L627-1097 Screening compound: N-[1-(3,4-dimethylphenyl)ethyl]-4-{[1-methyl-3-(pyrrolidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]methyl}benzamide

L627-1097 Screening compound: N-[1-(3,4-dimethylphenyl)ethyl]-4-{[1-methyl-3-(pyrrolidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]methyl}benzamide
L627-1097 Screening compound: N-[1-(3,4-dimethylphenyl)ethyl]-4-{[1-methyl-3-(pyrrolidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]methyl}benzamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L627-1097
N-[1-(3,4-dimethylphenyl)ethyl]-4-{[1-methyl-3-(pyrrolidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]methyl}benzamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L627-1097

Molecular Formula

C30H37N5O2 (C30 H37 N5 O2)

Compound Name

N-[1-(3,4-dimethylphenyl)ethyl]-4-{[1-methyl-3-(pyrrolidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]methyl}benzamide

IUPAC name

N-[1-(34-dimethylphenyl)ethyl]-4-{[1-methyl-3-(pyrrolidine-1-carbonyl)-1H4H5H6H7H-pyrazolo[43-c]pyridin-5-yl]methyl}benzamide

SMILES

CC(c1cc(C)c(C)cc1)NC(c1ccc(CN(CC2)Cc3c2n(C)nc3C(N2CCCC2)=O)cc1)=O

InChI

InChI=1S/C30H37N5O2/c1-20-7-10-25(17-21(20)2)22(3)31-29(36)24-11-8-23(9-12-24)18-34-16-13-27-26(19-34)28(32-33(27)4)30(37)35-14-5-6-15-35/h7-12,17,22H,5-6,13-16,18-19H2,1-4H3,(H,31,36)/t22-/m0/s1

InChI Key

UVDIPHRXDKMEGP-QFIPXVFZSA-N

MDL Number (MFCD)

MFCD27466133

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

499.66

Hydrogen Bond Acceptors Count

6.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

8.00

Number of Nitrogen and Oxygen Atoms

7

Partition Coefficient, logP

3.765

Distribution Coefficient, logD

-2.554

Water Solubility, LogSw

-3.99

Polar Surface Area

59.241

Acid Dissociation Constant (pKa)

11.57

Base Dissociation Constant (pKb)

13.72

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

43.30

L627-1097 in Drug Discovery

Included in Screening Libraries

Anticancer Library (62698 compounds)

CNS Targets (44014 compounds)

Cysteine Proteases Inhibitors Library (7839 compounds)

Hsp90-Targeted Library (11355 compounds)

Nucleic Acid Ligands (8311 compounds)

Ion Channels Focused Library (26372 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Nervous system
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Nervous system
  • Cardiovascular
  • Skin
  • Metabolic
  • Endocrine
  • Immune system
  • Cancer
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Immune system
  • Infections
  • Cancer
  • Musculoskeletal
  • Nervous system
  • Hemic and lymphatic
  • Immune system
  • Nervous system
  • Cardiovascular
Targets:
  • Proteases
  • Ion Channels

References: we are preparing a list of scientific research reports with L627-1097 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L627-1097?
Check Price and Availability of L627-1097, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L627-1097 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L627-1097
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L627-1097
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L627-1097 available by request